Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 13Rectal Neoplasms 5Neoplasm Metastasis 4Cholangiocarcinoma 4Stomach Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Adenocarcinoma Of Esophagus 3Ovarian Neoplasms 2Neoplasms 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pathologic Complete Response 1Lung Neoplasms 1Gastroesophageal Adenocarcinoma 1Endometrial Neoplasms 1Disease Progression 1Central Nervous System Neoplasms 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Rectal Cancer 1Adenocarcinoma of the Lower Rectum 1Adenocarcinoma 1

Interventions

Bevacizumab 39atezolizumab 26durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Sorafenib 7Immunoglobulin G 7regorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Folfox protocol × 90 days × Clear all
NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Completed
21 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07543783 2026-04-28

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Third Affiliated Hospital, Sun Yat-Sen University

Phase 2 Not yet recruiting
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Tongji Hospital

Phase 1/2 Not yet recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡